The inaugural neuroscienceCME TV broadcast is titled "Weight Gain with the Atypicals: How to Screen, Monitor, and Intervene." Premiering Wednesday, March 21, 2007, from 12:00 p.m.-1:00 p.m. ET, the activity will focus on recognizing the impact of weight gain associated with atypical antipsychotics and developing strategies to screen, monitor, and intervene to improve outcomes in patients with schizophrenia. The recorded satellite broadcast will re-air from 3:00 p.m.-4:00 p.m. ET. This CE activity will also be available as an archived webcast, podcast, and telephone audioconference shortly after the live broadcast, and available as a videotape or multimedia CD-ROM in April 2007.
There is no fee for participation in this activity, or to obtain a CE certificate; however, registration is required. Three forms of registration are accepted:
Online: Visit the activity details page at http://www.neuroscienceCME.com/cmea.asp?ID=217 and click the Register icon.
Phone: Call 877.CME.PROS (877.263.7767).
Fax: Visit the activity details page at http://www.neuroscienceCME.com/cmea.asp?ID=217, print and complete the activity details form, and fax to 240.243.1033.
Statement of Need:
Obesity is reaching epidemic proportions in the United States. Its prevalence in U.S. adults doubled between 1980 and 2002, and a recent report indicates that the obesity rate in 2003-2004 reached 32.2%. Patients with serious mental health issues such as schizophrenia and bipolar disorder are prone to concomitant metabolic problems, such as metabolic syndrome, diabetes, and obesity. In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial, more than one-third of males and one-half of all females fit the metabolic syndrome criteria, as defined by Adult Treatment Panel III (ATP III). Physicians treating patients with schizophrenia need to be aware of the impact of overweight and obesity on their patients' wellness and how they can screen, monitor, and intervene to address this healthcare crisis. At the Summer 2006 Commissioners Meeting of the National Association of State Mental Health Program Directors, the medical directors recommended that healthcare providers 1) screen for general health with priority for high-risk conditions (e.g., diabetes, cardiovascular disease), 2) screen, monitor, and intervene for medication-related risk factors, such as risk of metabolic syndrome with use of atypical antipsychotics, and 3) provide treatment per practice guidelines. In this live and interactive, evidence-based neuroscienceCME TV activity, the experts will explore the challenges clinicians face when managing weight gain associated with atypical antipsychotics, and develop strategies to screen, monitor, and intervene to improve outcomes in their patients with schizophrenia.
Moderator:
Charles B. Nemeroff, MD, PhD
Reunette W. Harris Professor and Chairman
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, GA
Faculty:
Robert R. Conley, MD
Professor of Psychiatry & Pharmacy Science
University of Maryland School of Medicine
Baltimore, MD
John W. Newcomer, MD
Professor of Psychiatry, Psychology, and Medicine
Medical Director, Center for Clinical Studies
Washington University School of Medicine
St. Louis, MO
Learning Objectives:
At the end of this CE activity, participants should be able to:
- Apply recent guidelines to improve clinical skills in screening, monitoring, and intervention in patients with risk for metabolic disorders per APA, IPAP, and NASMHPD guidelines.
- Employ proper technique for measuring waist circumference and translating the measurement into cardiovascular risk.
- Distinguish initiation, choice of agent, duration of trial, and pharmacokinetic issues (metabolites, bioavailability) of antipsychotic agents to minimize risk from weight gain .
Target Audience:
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.
Commercial Support:
CME Outfitters, LLC, gratefully acknowledges an educational grant from Pfizer Inc. in support of this CE activity.
Credit Information:
This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (ANCC)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
Full CE credit information is available at http://www.neuroscienceCME.com/cmea.asp?ID=217
About CME Outfitters:
CME Outfitters develops and distributes live, recorded, print, and web-based educational activities to thousands of clinicians each year and offers expert accreditation services for non-accredited organizations. For a complete catalog of certified activities, please visit http://www.cmeoutfitters.com, http://www.neuroscienceCME.com, or call 877.CME.PROS (877.263.7767).
About neuroscienceCME:
neuroscienceCME.com is the premier web portal serving clinicians, educators, and researchers in the neurosciences. Launched in October 2006, neuroscienceCME.com was custom designed to fill an identified gap in online resources for professionals around the world who are practicing in areas related to psychiatry, sleep disorders, addiction and substance abuse, ADHD, and other areas related to brain function. The site's primary mission is to be the professional's central forum for accessing, debating, synthesizing, and implementing the latest findings and best practices in the neurosciences.
To view all recent neuroscienceCME press releases, visit http://www.neuroscienceCME.com and click on "News Room" or visit http://www.prweb.com and search for "neuroscienceCME."
Clinical Compass, a bi-weekly e-newsletter published by CME Outfitters, is a convenient way to stay informed of all neuroscienceCME news and information. To subscribe, visit http://www.neuroscienceCME.com and click on "Subscribe to Clinical Compass."
Contact: Jessica Primanzon
CME Outfitters, LLC
240.243.1308 direct
240.243.1033 fax
# # #
.jpg)
Comment Preview